SP Group (SPG) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
25 Mar, 2026Executive summary
Achieved record Q4 2025 performance, with revenue up nearly 14% and EBITDA up 26% in the quarter, demonstrating resilience despite project postponements and global uncertainties.
Full-year revenue grew 0.9% to DKK 2,948 million, with EBITDA margin at 20.2% and EBT margin at 11.7%.
Acquired Idé-Pro in December 2025 for DKK 700 million, expected to contribute DKK 450 million in revenue and DKK 100 million in EBITDA, with synergies of DKK 20-25 million by 2027.
Expanded U.S. healthcare production with Atlanta factory operational since January 2025 and increased activity in India.
Subcontracting work grew almost 6%, while revenue from own products declined by 10% due to project postponements.
Financial highlights
Revenue: DKK 2,948 million (+0.9% year-over-year).
EBITDA: DKK 595 million (+1.1% year-over-year), margin 20.2%.
EBT: DKK 345 million (+0.1% year-over-year), EBT margin 11.7%.
Earnings per share, diluted, rose by 2.3% to DKK 22.1.
Cash flow from operations: DKK 393 million, down DKK 117 million due to increased inventory.
Outlook and guidance
2026 revenue growth expected at 15%-23%, EBITDA margin 19%-21%, EBT margin 11%-13%.
Growth driven by new products, customers, and Idé-Pro acquisition (approx. 15% of growth).
Assumes Middle East conflict de-escalates soon; risks from raw material and energy prices acknowledged.
Long-term ambition: revenue growth 6%-9% annually to DKK 4.5 billion by 2030, EBT margin 12%-14%.
Latest events from SP Group
- Record Q4 and strong 2026 growth outlook, boosted by Idé-Pro acquisition.SPG
Q4 202525 Mar 2026 - Strong H1 2024 growth, upgraded outlook, and international expansion led by healthcare sales.SPG
Q2 202423 Jan 2026 - Record revenue and margin growth in 2024; cautious 2025 outlook with focus on own products.SPG
Q4 202426 Dec 2025 - Acquisition enables in-house toolmaking, new materials, and DKK 20–25m annual synergies.SPG
M&A Announcement19 Dec 2025 - Record Q1 growth and margin gains led by Healthcare; outlook steady amid global risks.SPG
Q1 202524 Nov 2025 - Q2 slowdown led to lower H1 results and a flat outlook, but margins and investments remain strong.SPG
Q2 202523 Nov 2025 - 2025 guidance maintained as order backlog and new projects offset lower sales and margins.SPG
Q3 202520 Nov 2025 - Revenue down 3.3% in 9M 2025, but guidance and growth outlook remain stable.SPG
Q3 202520 Nov 2025 - H1 2025 saw revenue and earnings decline, but margin guidance and growth projects remain on track.SPG
Q2 202520 Aug 2025